NASDAQ:LJPC La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free LJPC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$3.12▼$6.2252-Week Range N/AVolume66,708 shsAverage Volume158,476 shsMarket Capitalization$155.11 millionP/E Ratio51.84Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About La Jolla Pharmaceutical Stock (NASDAQ:LJPC)La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Read More Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. LJPC Stock News HeadlinesMay 8, 2024 | finance.yahoo.comInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressMarch 27, 2024 | msn.comLa Jolla small business owners want lawful path to conduct business on the beachDecember 19, 2023 | health.usnews.comScripps Green HospitalSeptember 25, 2023 | fool.comLa Jolla Pharmaceutical (NASDAQ: LJPC)July 27, 2023 | finance.yahoo.comHepatorenal Syndrome Treatment Global Market Report 2023May 16, 2023 | marketwatch.comThalassemia Market Research | 2023-2030May 11, 2023 | businesswire.comResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...May 10, 2023 | marketwatch.comKidney (Renal) Fibrosis Market Report | Research Across The World 2031May 8, 2023 | marketwatch.comKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031May 5, 2023 | marketwatch.comBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.May 4, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031May 3, 2023 | usnews.comLa Jolla High SchoolApril 19, 2023 | markets.businessinsider.comCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?April 8, 2023 | marketwatch.comThalassemia Market Complete Overview till 2030April 7, 2023 | marketwatch.comKidney Fibrosis Treatment Market-An Exclusive Study On Upcoming Trends And Growth Opportunities From 2023-2030April 6, 2023 | marketwatch.comKidney/Renal Fibrosis Treatment Market Size By 2031March 27, 2023 | marketwatch.comGlobal Thalassemia Market Size 2023 to 2026 Size and Share Survey ReportMarch 22, 2023 | marketwatch.comKidney Fibrosis Treatment Market Major Players, Anlysis and Forecast till 2031March 20, 2023 | marketwatch.comKidney/Renal Fibrosis Treatment Market Analysis 2023-2028, Newly Upgraded ReportMarch 18, 2023 | health.usnews.comScripps La Jolla HospitalsMarch 17, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Share, Segmentation and Forecast 2023-2028March 17, 2023 | marketwatch.comGlobal Fibrodysplasia Ossificans Progressiva Drug Market Size by Application (Hospital, Clinic, Research Center) Forecast from 2023 to 2028March 15, 2023 | marketwatch.comHeavy Metal Poisoning Drugs Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027March 13, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Research Report 2023-2028 with Top Countries DataMarch 12, 2023 | marketwatch.comGlobal Thalassemia Market Growth Prospects, Geography, Drivers, and Restraints 2023 – 2030 By VMReportsSee More Headlines Company Calendar Last Earnings5/16/2022Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LJPC CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone(617) 715-3600Fax858-626-2851Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio51.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$19.66 million Net Margins8.54% Pretax Margin8.64% Return on Equity-5.46% Return on Assets4.00% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.52 Sales & Book Value Annual Sales$75.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.95 Book Value($2.94) per share Price / BookN/AMiscellaneous Outstanding Shares24,937,000Free Float15,885,000Market Cap$155.11 million OptionableOptionable Beta2.39 Key ExecutivesMr. Larry G. Edwards (Age 50)Pres, CEO & Director Comp: $858.87kMr. Michael S. Hearne (Age 59)CFO & Sec. Comp: $207.38kMs. Paula RusuVP of OperationsMs. Sandra VedrickSr. Director of Investor Relations & HRMr. Luke Seikkula (Age 58)Sr. VP of Pharmaceutical Operations Dr. Lakhmir S. Chawla M.D. (Age 51)Consultant Mr. Stewart M. Kroll (Age 63)Chief Devel. Officer Mr. Mark D. WilliamsSr. VP of Medical AffairsMr. Tony N. Hodges FACPM.D., Chief Medical OfficerMore ExecutivesKey CompetitorsGritstone bioNASDAQ:GRTSValnevaNASDAQ:VALNiTeos TherapeuticsNASDAQ:ITOSLexeo TherapeuticsNASDAQ:LXEOKyverna TherapeuticsNASDAQ:KYTXView All Competitors LJPC Stock Analysis - Frequently Asked Questions How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to analysts' expectations of $13.10 million. La Jolla Pharmaceutical had a negative trailing twelve-month return on equity of 5.46% and a net margin of 8.54%. What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO? 8 employees have rated La Jolla Pharmaceutical Chief Executive Officer George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among the company's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA). This page (NASDAQ:LJPC) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding La Jolla Pharmaceutical You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share La Jolla Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.